TY - JOUR
T1 - The effect of recombinant factor viia on coagulopathic pigs with grade V liver injuries
AU - Schreiber, Martin A.
AU - Holcomb, John B.
AU - Hedner, Ulla
AU - Brundage, Susan I.
AU - Macaitis, Joseph M.
AU - Hoots, Keith
PY - 2002/8
Y1 - 2002/8
N2 - Background Recombinant factor VIIa (rFVIIa) has been used to decrease bleeding in a number of settings including hemophilia, liver transuplantation, intractable bleeding, and cirrhosis. Experience in the trauma setting is limited. This study was performed to determine whether rFVIIa would reduce bleeding after a grade V liver injury in hypothermic, dilutionally coagulopathic pigs when used as an adjunct to abdominal packing and to determine whether increasing the dose of the drug increased its hemostatic efficacy. Methods Thirty animals were randomized to receive 180 μg/kg of rFVIIa, 720 μg/kg of rFVIIa, or vehicle buffer control. After laparotomy and suplenectomy, animals underwent a 60% blood volume isovolemic exchange transfusion with 5% human albumin. The animals’ temperature was maintained at 33°C and a standardized grade V liver injury was made with a liver clamp. Thirty seconds after injury, the abdomen was packed with laparotomy suponges, resuscitation was initiated, and blinded therapy was given. Animals were resuscitated to their baseline mean arterial pressure and the study was continued for 2 hours. Serial coagulation parameters were measured at the temperature they were drawn. After the study period, surviving animals were killed, posttreatment blood loss was measured, and an autopsy was performed. Results Ten animals were randomized to each group. After administration of study drug, factor VII clotting activity (FVII;C) was higher in the 720-μg/kg group than in the 180-μg/kg group (p < 0.01). FVII;C was higher in both treatment groups than in the control group (p < 0.01). The mean prothrombin time was shorter in the treatment groups than in the control group (p < 0.05). Mean arterial pressure was lower in the control group than in the treatment groups throughout the study (p < 0.01). Mean blood loss was less in the treatment groups than in the control group (p = 0.03). Mortality was not different between groups. There were no differences between the groups that received rFVIIa in any measured parameters except for FVII;C. Liver injuries were similar between groups and there was no evidence of microthrombosis on lung histology. Conclusion rFVIIa reduces blood loss in hypothermic, dilutionally coagulopathic pigs with grade V injuries when used as an adjunct to packing. Increasing the dose does not enhance the hemostatic effect.
AB - Background Recombinant factor VIIa (rFVIIa) has been used to decrease bleeding in a number of settings including hemophilia, liver transuplantation, intractable bleeding, and cirrhosis. Experience in the trauma setting is limited. This study was performed to determine whether rFVIIa would reduce bleeding after a grade V liver injury in hypothermic, dilutionally coagulopathic pigs when used as an adjunct to abdominal packing and to determine whether increasing the dose of the drug increased its hemostatic efficacy. Methods Thirty animals were randomized to receive 180 μg/kg of rFVIIa, 720 μg/kg of rFVIIa, or vehicle buffer control. After laparotomy and suplenectomy, animals underwent a 60% blood volume isovolemic exchange transfusion with 5% human albumin. The animals’ temperature was maintained at 33°C and a standardized grade V liver injury was made with a liver clamp. Thirty seconds after injury, the abdomen was packed with laparotomy suponges, resuscitation was initiated, and blinded therapy was given. Animals were resuscitated to their baseline mean arterial pressure and the study was continued for 2 hours. Serial coagulation parameters were measured at the temperature they were drawn. After the study period, surviving animals were killed, posttreatment blood loss was measured, and an autopsy was performed. Results Ten animals were randomized to each group. After administration of study drug, factor VII clotting activity (FVII;C) was higher in the 720-μg/kg group than in the 180-μg/kg group (p < 0.01). FVII;C was higher in both treatment groups than in the control group (p < 0.01). The mean prothrombin time was shorter in the treatment groups than in the control group (p < 0.05). Mean arterial pressure was lower in the control group than in the treatment groups throughout the study (p < 0.01). Mean blood loss was less in the treatment groups than in the control group (p = 0.03). Mortality was not different between groups. There were no differences between the groups that received rFVIIa in any measured parameters except for FVII;C. Liver injuries were similar between groups and there was no evidence of microthrombosis on lung histology. Conclusion rFVIIa reduces blood loss in hypothermic, dilutionally coagulopathic pigs with grade V injuries when used as an adjunct to packing. Increasing the dose does not enhance the hemostatic effect.
KW - Coagulopathy
KW - Hemorrhage
KW - Hypothermia
KW - Liver injury
KW - Recombinant factor VIIa
KW - Swine
UR - http://www.scopus.com/inward/record.url?scp=0036686745&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0036686745&partnerID=8YFLogxK
U2 - 10.1097/00005373-200208000-00011
DO - 10.1097/00005373-200208000-00011
M3 - Article
C2 - 12169930
AN - SCOPUS:0036686745
SN - 2163-0755
VL - 53
SP - 252
EP - 259
JO - Journal of Trauma and Acute Care Surgery
JF - Journal of Trauma and Acute Care Surgery
IS - 2
ER -